疗效和安全性-话题@MedSci

#疗效和安全性#

431篇内容 | 4571人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1721201, encodeId=c29b1e21201f1, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Palliat Med：整形外科原理指导下的糖尿病足溃疡创面修复手术具有良好的疗效和安全性, objectType=article, longId=728173, objectId=9f8ae2817371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f8ae2817371, replyNumber=0, likeNumber=110, createdTime=2023-03-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f8ae2817371, moduleTitle=Ann Palliat Med：整形外科原理指导下的糖尿病足溃疡创面修复手术具有良好的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f8ae2817371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721221, encodeId=73f21e2122164, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=A&R：肉毒杆菌毒素对继发于系统性硬化症的雷诺现象成人的疗效和安全性：一项随机、双盲、安慰剂对照的多中心研究, objectType=article, longId=739377, objectId=aee1e39377f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aee1e39377f6, replyNumber=0, likeNumber=106, createdTime=2022-10-22, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aee1e39377f6, moduleTitle=A&R：肉毒杆菌毒素对继发于系统性硬化症的雷诺现象成人的疗效和安全性：一项随机、双盲、安慰剂对照的多中心研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aee1e39377f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721190, encodeId=27a51e21190b9, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Rheum Dis：瑞莎珠单抗治疗活动性银屑病关节炎的疗效和安全性：KEEPsAKE 1试验24周结果, objectType=article, longId=725974, objectId=3d38e2597445, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d38e2597445, replyNumber=0, likeNumber=76, createdTime=2023-01-29, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d38e2597445, moduleTitle=Ann Rheum Dis：瑞莎珠单抗治疗活动性银屑病关节炎的疗效和安全性：KEEPsAKE 1试验24周结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d38e2597445)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721176, encodeId=78221e21176ec, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Arthritis Rheumatol：单克隆抗体Guselkumab治疗活动性银屑病的长期疗效和安全性, objectType=article, longId=301766, objectId=95c3301e667c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95c3301e667c, replyNumber=0, likeNumber=108, createdTime=2023-02-01, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95c3301e667c, moduleTitle=Arthritis Rheumatol：单克隆抗体Guselkumab治疗活动性银屑病的长期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95c3301e667c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721200, encodeId=a9391e21200bf, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Int Arch Allergy Immunol：基于不同干预时间的青蒿舌下免疫疗法对季节性过敏性鼻炎患者的临床疗效和安全性分析, objectType=article, longId=728274, objectId=fad7e282740b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fad7e282740b, replyNumber=0, likeNumber=92, createdTime=2022-09-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fad7e282740b, moduleTitle=Int Arch Allergy Immunol：基于不同干预时间的青蒿舌下免疫疗法对季节性过敏性鼻炎患者的临床疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fad7e282740b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721188, encodeId=334f1e21188d9, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Intern Med：射血分数降低的心力衰竭患者虚弱程度对达格列净疗效和安全性的影响, objectType=article, longId=725475, objectId=d648e254756f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d648e254756f, replyNumber=0, likeNumber=85, createdTime=2023-03-14, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d648e254756f, moduleTitle=Ann Intern Med：射血分数降低的心力衰竭患者虚弱程度对达格列净疗效和安全性的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d648e254756f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721208, encodeId=06671e21208f7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Comput Intell Neurosci：过敏性鼻炎伴糖尿病患者中，富马酸鲁帕他定联合穴位敷贴的疗效和安全性如何？, objectType=article, longId=731159, objectId=d72de31159fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d72de31159fb, replyNumber=0, likeNumber=95, createdTime=2023-03-01, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d72de31159fb, moduleTitle=Comput Intell Neurosci：过敏性鼻炎伴糖尿病患者中，富马酸鲁帕他定联合穴位敷贴的疗效和安全性如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d72de31159fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721193, encodeId=45e91e211930d, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性, objectType=article, longId=726649, objectId=3c23e2664918, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c23e2664918, replyNumber=0, likeNumber=100, createdTime=2023-03-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c23e2664918, moduleTitle=J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c23e2664918)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721146, encodeId=af771e21146e8, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Br J Dermatol：ixekizumab与guselkumab治疗中重度斑块状银屑病的疗效和安全性, objectType=article, longId=292150, objectId=0b012921503e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b012921503e, replyNumber=0, likeNumber=102, createdTime=2022-01-07, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b012921503e, moduleTitle=Br J Dermatol：ixekizumab与guselkumab治疗中重度斑块状银屑病的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b012921503e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721155, encodeId=d18d1e21155aa, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J. Clin. Med：依鲁替尼治疗 CLL 患者的长期疗效和安全性：真实生活体验。 , objectType=article, longId=293868, objectId=f6e9293868c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6e9293868c5, replyNumber=0, likeNumber=99, createdTime=2022-06-08, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6e9293868c5, moduleTitle=J. Clin. Med：依鲁替尼治疗 CLL 患者的长期疗效和安全性：真实生活体验。 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6e9293868c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721164, encodeId=ce1c1e21164a5, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究, objectType=article, longId=299023, objectId=2d572990238b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d572990238b, replyNumber=0, likeNumber=112, createdTime=2022-05-01, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d572990238b, moduleTitle=Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d572990238b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721121, encodeId=34d81e21121e9, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clin Cancer Res：Tepotinib治疗MET外显子14 (METex14)跳跃NSCLC患者的疗效和安全性：VISION研究, objectType=article, longId=220835, objectId=9070220835a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9070220835a6, replyNumber=0, likeNumber=142, createdTime=2022-05-23, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9070220835a6, moduleTitle=Clin Cancer Res：Tepotinib治疗MET外显子14 (METex14)跳跃NSCLC患者的疗效和安全性：VISION研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9070220835a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721191, encodeId=35b61e2119107, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Circulation：达格列净对不同血压2型糖尿病的疗效和安全性分析, objectType=article, longId=726333, objectId=5f1ae263330a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f1ae263330a, replyNumber=0, likeNumber=126, createdTime=2023-03-14, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f1ae263330a, moduleTitle=Circulation：达格列净对不同血压2型糖尿病的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f1ae263330a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721197, encodeId=9e271e211974b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=AP&T: 新型钾竞争性酸阻滞剂克维拉赞(keverprazan)治疗糜烂性食管炎的疗效和安全性分析, objectType=article, longId=728067, objectId=b454e280675c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b454e280675c, replyNumber=0, likeNumber=101, createdTime=2022-08-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b454e280675c, moduleTitle=AP&T: 新型钾竞争性酸阻滞剂克维拉赞(keverprazan)治疗糜烂性食管炎的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b454e280675c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721173, encodeId=bd381e2117313, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, objectType=article, longId=301205, objectId=7d6a3012059f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6a3012059f, replyNumber=0, likeNumber=105, createdTime=2022-06-13, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6a3012059f, moduleTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d6a3012059f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721213, encodeId=f9061e2121395, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet Respir Med：法国研究中心报道BPA与riociguat在不可手术的CTEPH患者中的疗效和安全性。, objectType=article, longId=735094, objectId=332de3509446, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=332de3509446, replyNumber=0, likeNumber=92, createdTime=2023-06-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=332de3509446, moduleTitle=Lancet Respir Med：法国研究中心报道BPA与riociguat在不可手术的CTEPH患者中的疗效和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=332de3509446)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721207, encodeId=59711e2120722, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性, objectType=article, longId=730645, objectId=8303e3064580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8303e3064580, replyNumber=0, likeNumber=103, createdTime=2022-06-30, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8303e3064580, moduleTitle=ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8303e3064580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721131, encodeId=41a41e21131eb, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, objectType=article, longId=221301, objectId=e3df221301c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3df221301c8, replyNumber=0, likeNumber=94, createdTime=2022-06-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3df221301c8, moduleTitle=Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3df221301c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721179, encodeId=dce51e211794a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JAMA Oncol：卡罗妥昔单抗联合帕唑帕尼治疗晚期血管肉瘤的疗效和安全性, objectType=article, longId=302293, objectId=2c1c3022933d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c1c3022933d, replyNumber=0, likeNumber=112, createdTime=2022-11-18, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c1c3022933d, moduleTitle=JAMA Oncol：卡罗妥昔单抗联合帕唑帕尼治疗晚期血管肉瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c1c3022933d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721175, encodeId=52951e2117508, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clin Cancer Res：雷莫芦单抗治疗晚期胆道癌的疗效和安全性, objectType=article, longId=301819, objectId=4f3d301819ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f3d301819ac, replyNumber=0, likeNumber=112, createdTime=2022-07-15, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f3d301819ac, moduleTitle=Clin Cancer Res：雷莫芦单抗治疗晚期胆道癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f3d301819ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性

2020-05-29

经常头晕

#疗效和安全性#

Ann Palliat Med：整形外科原理指导下的糖尿病足溃疡创面修复手术具有良好的疗效和安全性

2023-03-19

经常头晕

#疗效和安全性#

A&R：肉毒杆菌毒素对继发于系统性硬化症的雷诺现象成人的疗效和安全性：一项随机、双盲、安慰剂对照的多中心研究

2022-10-22

经常头晕

#疗效和安全性#

Ann Rheum Dis：瑞莎珠单抗治疗活动性银屑病关节炎的疗效和安全性：KEEPsAKE 1试验24周结果

2023-01-29

经常头晕

#疗效和安全性#

Arthritis Rheumatol：单克隆抗体Guselkumab治疗活动性银屑病的长期疗效和安全性

2023-02-01

经常头晕

#疗效和安全性#

Int Arch Allergy Immunol：基于不同干预时间的青蒿舌下免疫疗法对季节性过敏性鼻炎患者的临床疗效和安全性分析

2022-09-06

经常头晕

#疗效和安全性#

Ann Intern Med：射血分数降低的心力衰竭患者虚弱程度对达格列净疗效和安全性的影响

2023-03-14

经常头晕

#疗效和安全性#

Comput Intell Neurosci：过敏性鼻炎伴糖尿病患者中，富马酸鲁帕他定联合穴位敷贴的疗效和安全性如何？

2023-03-01

经常头晕

#疗效和安全性#

J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性

2023-03-06

经常头晕

#疗效和安全性#

Br J Dermatol：ixekizumab与guselkumab治疗中重度斑块状银屑病的疗效和安全性

2022-01-07

经常头晕

#疗效和安全性#

J. Clin. Med：依鲁替尼治疗 CLL 患者的长期疗效和安全性：真实生活体验。

2022-06-08

经常头晕

#疗效和安全性#

Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究

2022-05-01

经常头晕

#疗效和安全性#

Clin Cancer Res：Tepotinib治疗MET外显子14 (METex14)跳跃NSCLC患者的疗效和安全性：VISION研究

2022-05-23

经常头晕

#疗效和安全性#

Circulation：达格列净对不同血压2型糖尿病的疗效和安全性分析

2023-03-14

经常头晕

#疗效和安全性#

AP&T: 新型钾竞争性酸阻滞剂克维拉赞(keverprazan)治疗糜烂性食管炎的疗效和安全性分析

2022-08-06

经常头晕

#疗效和安全性#

Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性

2022-06-13

经常头晕

#疗效和安全性#

Lancet Respir Med：法国研究中心报道BPA与riociguat在不可手术的CTEPH患者中的疗效和安全性。

2023-06-06

经常头晕

#疗效和安全性#

ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性

2022-06-30

经常头晕

#疗效和安全性#

Oncologist: Anlotinib（安罗替尼）联合S-1三线或后线治疗晚期NSCLC患者的疗效和安全性：II期临床研究

2022-06-06

经常头晕

#疗效和安全性#

JAMA Oncol：卡罗妥昔单抗联合帕唑帕尼治疗晚期血管肉瘤的疗效和安全性

2022-11-18

经常头晕

#疗效和安全性#

Clin Cancer Res：雷莫芦单抗治疗晚期胆道癌的疗效和安全性

2022-07-15

科室
- - 订阅+
  - 更多科室
工具
服务